CYTOSORBENTS MEDICAL INC

Cytosorbents Medical Inc. specializes in the development of advanced medical adsorption technologies for critical care applications in austere and battlefield environments. Their core capabilities center on designing and validating proprietary sorbent systems that selectively remove pathological substances from blood—particularly potassium and isoagglutinins—to treat life-threatening conditions such as hyperkalemia and transfusion-related complications. The company leverages expertise in biomedical engineering, plasma chemistry, and extracorporeal circuit integration to create compact, deployable renal support and plasma purification devices tailored for military and emergency medical use. Key differentiators include their focus on point-of-care solutions that function without refrigeration or complex infrastructure, enabling use by first responders and combat medics. Their technical approach combines surface-modified polymer sorbents with validated clinical pathways to achieve rapid, targeted toxin removal without systemic immunosuppression. The company has consistently partnered with the Department of Defense, delivering research and development solutions under SBIR programs focused on battlefield medicine. Their work supports DHA’s mission to enhance survivability in trauma and mass casualty scenarios through innovative, field-deployable medical countermeasures. Engagement patterns indicate a sustained relationship built on iterative SBIR Phase II and III transitions, with a clear emphasis on transitioning laboratory innovations into operational military medical systems. Cytosorbents operates primarily within NAICS 541715, conducting applied life sciences research focused on therapeutic device development rather than drug discovery. Their market positioning is niche but critical: they serve the intersection of trauma care, renal support, and military medicine with devices that fill unmet needs in hemodynamic instability management. Cytosorbents Medical Inc. is a small business headquartered in Princeton, New Jersey, with no federal certifications on record. The company maintains a focused presence in the U.S. government biomedical R&D market, leveraging its technical agility to respond to DoD’s urgent medical innovation priorities.